Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

April 21, 2025 — 08:17 am EDT Written by Zacks Equity Research for Zacks -> Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96.

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Eli Lilly’s experimental cholesterol drug doubled patients’ HDL, or good cholesterol, setting the stage for a race between the Indianapolis pharmaceutical company and Merck and Roche Holding ...

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...

That growth began last year with Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss.